ISRG Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ISRG is a high-quality long-term company, but based on the current setup it is not a clear buy right now for a beginner investor with a long-term focus and $50,000-$100,000 to deploy. I would hold and wait for a better entry rather than buy immediately at this level.
ISRG is in a mixed technical state. Momentum is positive: MACD histogram is above zero and expanding, suggesting near-term bullish pressure. However, the trend structure is not fully supportive because the moving averages are bearish (SMA_200 > SMA_20 > SMA_5), which points to an unstable or transitioning trend rather than a clean uptrend. RSI_6 at 73.0 is elevated and near overbought territory, so the stock may be stretched short term. Price at 426.01 is sitting just above Pivot 409.55 and near R1 420.44 / R2 427.17, which suggests limited upside room before resistance. Short-term pattern data also implies only modest near-term gains and a negative one-month expectation.
Recent news remains fundamentally supportive for the company. Intuitive Surgical reportedly delivered about $10.1B in FY2025 revenue, up 20.5% year over year, and Q1 showed a 58% increase in Da Vinci 5 system installations. The installed base reached 11,395, global procedures rose 12% year over year, and recurring accessories/instruments revenue was strong at $1.6B. These are durable growth signals tied to the company’s moat and installed-base model. The upcoming Q2 earnings date is 2026-07-16, which can act as a near-term catalyst if results remain strong.
The news flow is not showing a specific negative company event, but the broader policy backdrop includes concerns about reduced reporting frequency, which investors see as less transparent. Analyst sentiment has also become more cautious recently, with several firms cutting price targets. Technically, the stock looks stretched after a strong move, and the short-term pattern projection points to a possible decline over the next month. Congress trading was also net negative, with 2 sales and 0 purchases in the last 90 days.
Latest quarter financial details were not fully provided, but the available financial/news summary indicates strong growth trends. For FY2025, Intuitive Surgical generated about $10.1B in revenue, up 20.5% year over year, showing strong top-line acceleration. The latest quarter season available in the data is Q1 2026, which showed strong system placements and procedure growth, including a 58% increase in Da Vinci 5 installations and continued expansion in the installed base. The business also benefits from recurring revenue from accessories and instruments, which supports longer-term growth quality.
Analyst sentiment is still mixed but tilted positive overall. Recent moves include BofA lowering its target to $515 from $520 while keeping a Buy rating, Goldman cutting target to $558 while staying Buy, Barclays lowering to $651 but remaining Overweight, and Piper Sandler/Truist also maintaining bullish ratings despite lower targets. On the bearish side, Deutsche Bank cut its target to $366 and kept a Sell rating, and Mizuho is Neutral. The overall Wall Street view is constructive on the business fundamentals, but pros are clearly debating valuation, utilization risk, and margin expectations. In short: the bulls still like the moat and procedure growth, while the bears focus on valuation and a less favorable medtech backdrop.
